BridgeBio announced long-term efficacy data from the ATTRibute-CM trial showing acoramidis (Attruby) achieved a 44.7% reduction in all-cause mortality and 49.3% reduction in cardiovascular mortality at Month 54 compared to placebo. The drug demonstrated sustained clinical benefits including mitigation of NT-proBNP progression and maintained quality of life scores, with a favorable safety profile.

BridgeBio announced positive Phase 3 FORTIFY interim analysis results for BBP-418, an oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The drug showed early separation from placebo in ambulation tests at three months, with participants completing the 100-meter timed test approximately 31 seconds faster than placebo at 12 months. BBP-418 demonstrated a favorable safety profile comparable to placebo. The company plans to submit an NDA to the FDA in the first half of 2026, with a U.S. launch anticipated in late 2026/early 2027. If approved, BBP-418 could be the first approved therapy for LGMD2I/R9 and potentially the first for any form of LGMD.

BridgeBio Pharma stock surged 12.60% following William Blair's initiation of coverage with an Outperform rating and $93.03 price target. The analyst highlighted the company's accelerating Attruby launch, near-term NDA submissions for disease-modifying therapies, and a strong pipeline in rare genetic diseases including achondroplasia and autosomal dominant hypocalcemia. BridgeBio's products are positioned as next-generation alternatives to Pfizer's market-leading tafamidis.

Ten large-cap stocks experienced significant declines during the week of February 16-20, 2026. Genuine Parts Company led losses with a 19.51% drop following worse-than-expected Q4 results and downward EPS guidance. Other major decliners included Blue Owl Capital (14.07%), Okta (12.86%), Flutter Entertainment (11.86%), and BridgeBio Pharma (11.43%), driven by analyst downgrades, disappointing earnings, and tender offer announcements.

BridgeBio Pharma's compensation committee approved equity grants of 76,701 restricted stock units to 34 new employees on February 12, 2026. The grants vest over four years with one-fourth vesting after one year and the remainder vesting quarterly thereafter, subject to continued employment.

BridgeBio Pharma announced positive Phase 3 trial results for infigratinib in treating achondroplasia (dwarfism) in children, showing superior annualized height velocity compared to placebo. The company plans to submit FDA and regulatory applications in the second half of 2026. The stock surged 6.92% to $78.41, nearing its 52-week high.

The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.

BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis significantly reduces all-cause mortality in variant ATTR-CM populations, with a 69% risk reduction in mortality for patients with the V142I genetic variant.

The National Advertising Division will refer BridgeBio Pharma to government agencies after the company failed to participate in an NAD inquiry regarding claims about its Attruby medication's superiority over Pfizer's Vyndamax.

BridgeBio Pharma announced successful Phase 3 trial results for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I/R9, showing significant improvements in muscle function, glycosylation, and reduced muscle damage markers.

BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis reduces cardiovascular outcomes in ATTR-CM patients, with significant risk reduction observed as early as the first month of treatment and sustained through 30 months.

BridgeBio's encaleret demonstrated promising results in a Phase 2 study for post-surgical hypoparathyroidism, with 80% of participants achieving normal blood and urine calcium levels within 5 days of treatment, leading to plans for a registrational clinical study in 2026.